These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 19896449)

  • 1. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen.
    Skeiky YA; Dietrich J; Lasco TM; Stagliano K; Dheenadhayalan V; Goetz MA; Cantarero L; Basaraba RJ; Bang P; Kromann I; McMclain JB; Sadoff JC; Andersen P
    Vaccine; 2010 Jan; 28(4):1084-93. PubMed ID: 19896449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis.
    Xing Z; Charters TJ
    Expert Rev Vaccines; 2007 Aug; 6(4):539-46. PubMed ID: 17669008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.
    van Dissel JT; Soonawala D; Joosten SA; Prins C; Arend SM; Bang P; Tingskov PN; Lingnau K; Nouta J; Hoff ST; Rosenkrands I; Kromann I; Ottenhoff TH; Doherty TM; Andersen P
    Vaccine; 2011 Mar; 29(11):2100-9. PubMed ID: 21256189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. H1:IC31 vaccination is safe and induces long-lived TNF-α
    Mearns H; Geldenhuys HD; Kagina BM; Musvosvi M; Little F; Ratangee F; Mahomed H; Hanekom WA; Hoff ST; Ruhwald M; Kromann I; Bang P; Hatherill M; Andersen P; Scriba TJ;
    Vaccine; 2017 Jan; 35(1):132-141. PubMed ID: 27866772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization strategies against pulmonary tuberculosis: considerations of T cell geography.
    Horvath CN; Xing Z
    Adv Exp Med Biol; 2013; 783():267-78. PubMed ID: 23468114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice.
    Haile M; Hamasur B; Jaxmar T; Gavier-Widen D; Chambers MA; Sanchez B; Schröder U; Källenius G; Svenson SB; Pawlowski A
    Tuberculosis (Edinb); 2005; 85(1-2):107-14. PubMed ID: 15687034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.
    Andersen CS; Dietrich J; Agger EM; Lycke NY; Lövgren K; Andersen P
    Infect Immun; 2007 Jan; 75(1):408-16. PubMed ID: 17074845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is intranasal vaccination a feasible solution for tuberculosis?
    Giri PK; Khuller GK
    Expert Rev Vaccines; 2008 Nov; 7(9):1341-56. PubMed ID: 18980538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new vaccine against tuberculosis shows greater protection in a mouse model with progressive pulmonary tuberculosis.
    Castañon-Arreola M; López-Vidal Y; Espitia-Pinzón C; Hernández-Pando R
    Tuberculosis (Edinb); 2005; 85(1-2):115-26. PubMed ID: 15687035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.
    Norrby M; Vesikari T; Lindqvist L; Maeurer M; Ahmed R; Mahdavifar S; Bennett S; McClain JB; Shepherd BM; Li D; Hokey DA; Kromann I; Hoff ST; Andersen P; de Visser AW; Joosten SA; Ottenhoff THM; Andersson J; Brighenti S
    Vaccine; 2017 Mar; 35(12):1652-1661. PubMed ID: 28216183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.
    Brandt L; Skeiky YA; Alderson MR; Lobet Y; Dalemans W; Turner OC; Basaraba RJ; Izzo AA; Lasco TM; Chapman PL; Reed SG; Orme IM
    Infect Immun; 2004 Nov; 72(11):6622-32. PubMed ID: 15501795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.
    Geldenhuys H; Mearns H; Miles DJ; Tameris M; Hokey D; Shi Z; Bennett S; Andersen P; Kromann I; Hoff ST; Hanekom WA; Mahomed H; Hatherill M; Scriba TJ; ; van Rooyen M; Bruce McClain J; Ryall R; de Bruyn G;
    Vaccine; 2015 Jul; 33(30):3592-9. PubMed ID: 26048780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral delivery of BCG Moreau Rio de Janeiro gives equivalent protection against tuberculosis but with reduced pathology compared to parenteral BCG Danish vaccination.
    Clark SO; Kelly DL; Badell E; Castello-Branco LR; Aldwell F; Winter N; Lewis DJ; Marsh PD
    Vaccine; 2010 Oct; 28(43):7109-16. PubMed ID: 20708695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice.
    Luo Y; Wang B; Hu L; Yu H; Da Z; Jiang W; Song N; Qie Y; Wang H; Tang Z; Xian Q; Zhang Y; Zhu B
    Vaccine; 2009 Oct; 27(44):6179-85. PubMed ID: 19712772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neonatal vaccination with Mycobacterium bovis BCG: potential effects as a priming agent shown in a heterologous prime-boost immunization protocol.
    Rahman MJ; Fernández C
    Vaccine; 2009 Jun; 27(30):4038-46. PubMed ID: 19379788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.
    Brodin P; Majlessi L; Brosch R; Smith D; Bancroft G; Clark S; Williams A; Leclerc C; Cole ST
    J Infect Dis; 2004 Jul; 190(1):115-22. PubMed ID: 15195250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Strategies for the development of new tuberculosis vaccines].
    Fattorini L
    Minerva Med; 2007 Apr; 98(2):109-19. PubMed ID: 17519853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis.
    Tang C; Yamada H; Shibata K; Maeda N; Yoshida S; Wajjwalku W; Ohara N; Yamada T; Kinoshita T; Yoshikai Y
    J Infect Dis; 2008 May; 197(9):1263-74. PubMed ID: 18422438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization.
    Xing Z; Lichty BD
    Tuberculosis (Edinb); 2006; 86(3-4):211-7. PubMed ID: 16504584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.